Provided by Tiger Trade Technology Pte. Ltd.

Guardant Health Inc.

101.85
+3.493.55%
Post-market: 103.511.66+1.63%19:08 EST
Volume:2.27M
Turnover:229.10M
Market Cap:13.18B
PE:-31.71
High:102.70
Open:100.77
Low:97.52
Close:98.36
52wk High:120.74
52wk Low:34.88
Shares:129.37M
Float Shares:124.00M
Volume Ratio:0.78
T/O Rate:1.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2124
EPS(LYR):-3.5551
ROE:-4584.47%
ROA:-19.64%
PB:-37.17
PE(LYR):-28.65

Loading ...

Guardant Health nimmt an der Barclays Global Healthcare Conference in Miami Beach teil

Reuters
·
Feb 04

Guardant reports publication of circulating tumor DNA for MRD detection study

TIPRANKS
·
Feb 02

Guardant Reveal Blood Test Improves Recurrence Prediction in Stage III Colon Cancer Patients

Reuters
·
Feb 02

UBS Adjusts Price Target on Guardant Health to $175 From $110, Maintains Buy Rating

MT Newswires Live
·
Jan 31

Guardant Health Inc. to Report Fourth Quarter and Full Year 2025 Financial Results

Reuters
·
Jan 30

Psychedelic: Analyst raises Compass, Definium, GH Research price targets

TIPRANKS
·
Jan 29

Guardant Health Is Maintained at Buy by Guggenheim

Dow Jones
·
Jan 27

FDA Approves New Colorectal Cancer Use For Guardant360 Might Change The Case For Investing In Guardant Health (GH)

Simply Wall St.
·
Jan 24

Analysts Are Bullish on These Healthcare Stocks: Vaxcyte (PCVX), Guardant Health (GH)

TIPRANKS
·
Jan 24

Leerink sees Court ruling as small win for Guardant, no change to patent risk

TIPRANKS
·
Jan 24

GH Research price target raised to $40 from $33 at RBC Capital

TIPRANKS
·
Jan 24

GH Research Is Maintained at Outperform by RBC Capital

Dow Jones
·
Jan 23

RBC Raises Price Target on GH Research to $40 From $33, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Jan 23

RBC Capital Remains a Buy on GH Research (GHRS)

TIPRANKS
·
Jan 23

Guardant Health Chief People Officer Terilyn J. Monroe Reports Sale of Common Shares

Reuters
·
Jan 23

FDA Approves Guardant360 CDx as Companion Diagnostic for BRAFTOVI Combination in BRAF V600E-Mutant Metastatic Colorectal Cancer

Reuters
·
Jan 22

Guardant Health Receives FDA Approval for Guardant360® Cdx as Companion Diagnostic for Braftovi® (Encorafenib) Combination in Patients With Braf V600e-Mutant Metastatic Colorectal Cancer

THOMSON REUTERS
·
Jan 22

Guardant Health announces multi-year strategic agreement with Merck

TIPRANKS
·
Jan 20

Guardant Health projects 2025 revenue to reach $981 million

Reuters
·
Jan 20

BRIEF-Guardant Health Announces Multi-Year Strategic Collaboration Agreement With Merck

Reuters
·
Jan 19